KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $155.4 million.

  • Amneal Pharmaceuticals' Net Cash Flow rose 44126.27% to $155.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.3 million, marking a year-over-year increase of 104322.83%. This contributed to the annual value of $20.3 million for FY2024, which is 6817.05% down from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Net Cash Flow is $155.4 million, which was up 44126.27% from $15.6 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Net Cash Flow's 5-year high stood at $155.4 million during Q3 2025, with a 5-year trough of -$172.9 million in Q2 2021.
  • For the 5-year period, Amneal Pharmaceuticals' Net Cash Flow averaged around -$5.3 million, with its median value being -$1.9 million (2022).
  • Per our database at Business Quant, Amneal Pharmaceuticals' Net Cash Flow plummeted by 88595.56% in 2023 and then skyrocketed by 113719.31% in 2024.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Net Cash Flow stood at -$54.1 million in 2021, then dropped by 5.3% to -$56.9 million in 2022, then skyrocketed by 105.8% to $3.3 million in 2023, then surged by 1137.19% to $40.8 million in 2024, then skyrocketed by 280.81% to $155.4 million in 2025.
  • Its last three reported values are $155.4 million in Q3 2025, $15.6 million for Q2 2025, and -$49.6 million during Q1 2025.